Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
34
NMRA Quote, Financials, Valuation and Earnings
Last price:
$1.83
Seasonality move
:
-54.68%
Day range:
$1.63 - $1.86
52-week range:
$0.61 - $3.25
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.07x
Volume:
3.7M
Avg. volume:
1.1M
1-year change:
-24.65%
Market cap:
$273.2M
Revenue:
--
EPS (TTM):
-$1.46
Analysts' Opinion
-
Consensus RatingNeumora Therapeutics, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 3 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $9.17, Neumora Therapeutics, Inc. has an estimated upside of 460.65% from its current price of $1.64.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.00 representing 100% downside risk from its current price of $1.64.
Fair Value
-
According to the consensus of 5 analysts, Neumora Therapeutics, Inc. has 460.65% upside to fair value with a price target of $9.17 per share.
NMRA vs. S&P 500
-
Over the past 5 trading days, Neumora Therapeutics, Inc. has underperformed the S&P 500 by -8.9% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Neumora Therapeutics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Neumora Therapeutics, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Neumora Therapeutics, Inc. reported revenues of --.
Earnings Growth
-
Neumora Therapeutics, Inc. has grown year-over-year earnings for 2 quarters straight. In the most recent quarter Neumora Therapeutics, Inc. reported earnings per share of -$0.35.
Enterprise value:
121.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-0.59x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$356K
Return On Assets:
-88.97%
Net Income Margin (TTM):
--
Return On Equity:
-102.63%
Return On Invested Capital:
-98.72%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$3.9M | -$640K | -$356K | -$156K | -$23K | |
| Operating Income | -$168.8M | -$250.6M | -$240.6M | -$76.6M | -$52.7M | |
| EBITDA | -$164.9M | -$250M | -$240.2M | -$76.5M | -$52.7M | |
| Diluted EPS | -$1.02 | -$1.85 | -$1.46 | -$0.45 | -$0.35 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $443.1M | -- | $525.7M | $348.6M | $177.1M | |
| Total Assets | $452M | -- | $544.7M | $352.5M | $177.8M | |
| Current Liabilities | $21M | -- | $29.1M | $31.7M | $25.8M | |
| Total Liabilities | $752.4M | -- | $32.1M | $31.8M | $45.7M | |
| Total Equity | -$300.4M | -- | $512.7M | $320.7M | $132.2M | |
| Total Debt | -- | -- | $2.7M | -- | $19.8M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$142.2M | -$184M | -$208.8M | -$33.5M | -$46.6M | |
| Cash From Investing | $42.7M | $41.9M | $27.1M | $157M | $51.3M | |
| Cash From Financing | $259.3M | $5.5M | $33.9M | $1.5M | -$136K | |
| Free Cash Flow | -$142.3M | -$189.4M | -$208.1M | -$33.5M | -$46.6M | |
NMRA
Sector
Market Cap
$273.2M
$28.1M
Price % of 52-Week High
50.31%
50.9%
Dividend Yield
0%
0%
Shareholder Yield
-6.42%
-1.55%
1-Year Price Total Return
-24.65%
-19.36%
Beta (5-Year)
--
0.498
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$1.75
200-day SMA
Buy
Level
$1.51
Bollinger Bands (100)
Sell
Level
1.6 - 2.4
Chaikin Money Flow
Sell
Level
-51.6M
20-day SMA
Sell
Level
$1.88
Relative Strength Index (RSI14)
Sell
Level
30.68
ADX Line
Sell
Level
22.58
Williams %R
Buy
Level
-87
50-day SMA
Sell
Level
$2.28
MACD (12, 26)
Sell
Level
-0.15
25-day Aroon Oscillator
Sell
Level
-88
On Balance Volume
Neutral
Level
18.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (28.5372)
Sell
CA Score
(Annual)
Level (-1.4134)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (13.6809)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (2)
Buy
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Neumora Therapeutics, Inc. is a clinical-stage biotechnology company. It offers a precision medicine approach for brain diseases through the integration of data science and neuroscience. The firm focuses on advancing medicines for therapeutically relevant targets implicated in CNS diseases, targeting novel mechanisms of action with best-in-class pharmacology. The company was founded by Paul L. Berns, Carol Suh and Mike Poole in November 2019 and is headquartered in Watertown, MA.
Stock Forecast FAQ
In the current month, NMRA has received 3 Buy ratings 2 Hold ratings, and 0 Sell ratings. The NMRA average analyst price target in the past 3 months is $9.17.
-
Where Will Neumora Therapeutics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Neumora Therapeutics, Inc. share price will rise to $9.17 per share over the next 12 months.
-
What Do Analysts Say About Neumora Therapeutics, Inc.?
Analysts are divided on their view about Neumora Therapeutics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Neumora Therapeutics, Inc. is a Sell and believe this share price will drop from its current level to $3.00.
-
What Is Neumora Therapeutics, Inc.'s Price Target?
The price target for Neumora Therapeutics, Inc. over the next 1-year time period is forecast to be $9.17 according to 5 Wall Street analysts, 3 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is NMRA A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Neumora Therapeutics, Inc. is a Buy. 3 of 5 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of NMRA?
You can purchase shares of Neumora Therapeutics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Neumora Therapeutics, Inc. shares.
-
What Is The Neumora Therapeutics, Inc. Share Price Today?
Neumora Therapeutics, Inc. was last trading at $1.83 per share. This represents the most recent stock quote for Neumora Therapeutics, Inc.. Yesterday, Neumora Therapeutics, Inc. closed at $1.64 per share.
-
How To Buy Neumora Therapeutics, Inc. Stock Online?
In order to purchase Neumora Therapeutics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get NMRA Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
NMRA
Sector
P/E ratio
--
24.09x
PEG ratio
--
-0.01x
P/B ratio
2.07x
1.83x
Price / LTM sales
--
1.59x
Growth Metrics
NMRA
Sector
Revenue growth
--
4.68%
Earnings growth
22.86%
10.88%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.33
-$0.18
Profitability
NMRA
Sector
Profitability FY 2024
-$631K
$3.6M
Return on invested capital
-98.72%
-31.87%
Return on assets
-88.97%
-28.18%
Return on equity
-102.63%
-37.89%
Earnings Date
Last Earnings Date
Nov
6
Next Earnings Date
Mar
2
Estimated Next Earnings Date
Feb
5
Balance Sheet
NMRA
Sector
Total cash
$171.5M
$26.2M
Short term investments
$165.4M
$25.7M
Total assets
$317M
$76.7M
Long term debt
$19.8M
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
57
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 64x
Buy
52
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 36x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
64
RGC alert for Jan 6
Regencell Bioscience Holdings Ltd. [RGC] is up 22.74% over the past day.
Buy
73
INOD alert for Jan 6
Innodata, Inc. [INOD] is up 4.84% over the past day.
Buy
65
AVAV alert for Jan 6
AeroVironment, Inc. [AVAV] is up 6.62% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
